Annual Report Contents

The Annual Report comprises:

  • Audited standalone and consolidated financial statements for FY 2025-26
  • Board's Report
  • Management Discussion and Analysis Report
  • Corporate Governance Report
  • Auditors' Reports
  • Other applicable disclosures

The report is available on the company website at www.takelimited.com.

Annual General Meeting Details

Date: Tuesday, September 29, 2026

Time: 12:00 PM

Venue: Through Video Conferencing/Other Audio-visual Means (VC/OAVM)

Record Date for E-voting: Tuesday, September 22, 2026

E-voting Period: September 26, 2026 (9:00 AM) to September 28, 2026 (5:00 PM)

EVSN: 260904016

AGM Agenda Items

Ordinary Businesses

1. Adoption of audited standalone financial statements for FY 2025-26

2. Adoption of audited consolidated financial statements for FY 2025-26

3. Reappointment of Mr. Parmeshvar Dhangare (DIN: 11410125) who retires by rotation

4. Appointment of M/s. A. Raghavendra Rao & Associates, Chartered Accountants as Statutory Auditors for 5 years

Special Business

5. Appointment of M/s. Hemang Satra & Associates (COP: 24235, PRC: 5684/2024) as Secretarial Auditor for 5 years (FY 2025-26 to 2029-30)

Financial Performance Highlights

Standalone Financials (₹ in Lakhs)

| Particulars | FY 2025-26 | FY 2024-25 |

| Total Income | 661.75 | 1,387.48 |

| Total Expenses | 374.82 | 374.54 |

| Profit before Tax | 286.93 | 1,012.94 |

| Profit after Tax | 271.91 | (6,973.56) |

| EPS (₹) | 0.18 | (4.71) |

Consolidated Financials (₹ in Lakhs)

| Particulars | FY 2025-26 | FY 2024-25 |

| Total Income | 6,087.26 | 1,021.90 |

| Revenue from Operations | 5,418.53 | 0 |

| Profit before Tax | 441.62 | 73.81 |

| Profit after Tax | 1,084.91 | 3,746.71 |

| EPS (₹) | 0.74 | 2.53 |

Board of Directors

As on March 31, 2026:

  • Mr. Parmeshvar Dhangare - Chairman and Non-executive Director
  • Mr. Sunil Patra - Managing Director and CFO (appointed May 19, 2026)
  • Mr. Vilas Munis - Non-executive Director
  • Ms. Pushpa Joshi - Independent Director
  • Mr. Kanwar Nitin Singh - Independent Director
  • Mr. Peeyush Sethia - Independent Director

Key Managerial Personnel

  • Ms. Vandana Gupta - Company Secretary and Compliance Officer

Changes in Board Composition during FY25-26

Resignations:

  • Ms. Kiran Sharma (ID) - April 2, 2025
  • Mr. Rangasami Seshadri (ID) - April 27, 2025
  • Mr. Ramesh Gopal (ID) - May 1, 2025
  • Dr. Chandrasekaran Nagarajan (ID) - May 1, 2025
  • Mr. Srinivasan Ramani Harikesanallur (NED) - December 1, 2025
  • Ms. Cecily Dheepa (NED) - December 31, 2025
  • Mr. Vedamirtham Venkatesan (ED) - December 31, 2025

Appointments:

  • Ms. Pushpa Joshi (ID) - May 24, 2025
  • Mr. Kanwar Nitin Singh (ID) - May 24, 2025
  • Mr. Peeyush Sethia (ID) - May 24, 2025
  • Ms. Cecily Dheepa (NED) - May 1, 2025
  • Mr. Vedamirtham Venkatesan (ED) - May 1, 2025
  • Mr. Parmeshvar Dhangare (Chairman) - December 12, 2025
  • Mr. Vilas Munis (NED) - February 11, 2026
  • Mr. Sunil Patra (MD & CFO) - May 19, 2026

Auditors

Statutory Auditors: M/s. A. Raghavendra Rao & Associates, Chartered Accountants (FRN: 003324S)

  • Appointed to fill casual vacancy after resignations of previous auditors
  • Issued qualified opinion on financial statements

Secretarial Auditors: M/s. Hemang Satra & Associates, Practicing Company Secretaries (COP: 24235)

  • Appointed for 5 years from FY 2025-26 to 2029-30

Internal Auditors: M/s. Tejas Nadkarni & Associates, Chartered Accountants (FRN: 135197W)

Audit Qualifications

Standalone Financial Statements

Qualification: Income tax assets (net) of ₹875.80 lakhs pertaining to assessment years up to March 31, 2021 are under dispute pending before various forums. The ultimate realizable value cannot be confirmed due to pending appeals.

Management Response: Amounts are fully recoverable upon completion of assessment/disposal of appeals. No impairment considered necessary.

Consolidated Financial Statements

Qualification: Income tax assets of ₹1,291.90 lakhs pertaining to assessment years up to March 31, 2026 are under dispute. The ultimate realizable value cannot be confirmed due to pending appeals.

Management Response: Amounts are fully recoverable upon completion of assessment/disposal of appeals. No impairment considered necessary.

Share Capital

Authorized Capital: ₹50,00,00,000 divided into:

  • 35,00,00,000 Equity Shares of ₹1/- each
  • 1,50,00,000 Preference Shares of ₹10/- each

Issued, Subscribed and Paid-up Capital: ₹14,79,34,000 divided into 14,79,34,000 Equity Shares of ₹1/- each

No change in share capital structure during the year.

Subsidiaries

  • TAKE Ventures Private Limited: Wholly owned subsidiary incorporated during the year
  • Navitas LLP: Existing subsidiary

The company has no associates or joint ventures.

Material Developments During FY25-26

1. Shifting of Registered Office: From No. 56, Old No. 116, 4th Floor, Ragas Building, Dr. Radhakrishnan Salai, Mylapore, Chennai - 600004 to No. B3, No. 9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai - 600102 (effective December 18, 2025)

2. Strategic Expansion into AI-driven Healthcare:

  • December 23, 2025: Announced AI-powered Diagnostic & Preventive Care Platform
  • February 10, 2026: Announced "One Minute Clinic" AI-enabled smart diagnostic units
  • February 17, 2026: Announced Scalable Unified AI Platform for healthcare providers
  • February 21, 2026: Integrated Anthropic's Claude AI capabilities
  • March 25, 2026: Launched "Take.Health" AI-driven digital health platform

3. Subsidiary Formation: Incorporated TAKE Ventures Private Limited as wholly owned subsidiary

Post-Year End Developments

1. April 6, 2026: Launched Innovation Fund with initial corpus of ₹50 million (₹5 crore) for AI, deep tech and digital health startups

2. April 17, 2026: Announced entry into longevity and anti-ageing market in India

3. Change of Name: Members approved change from "TAKE SOLUTIONS LIMITED" to "TAKE LIMITED" through Postal Ballot on June 16, 2026. Certificate received on June 25, 2026.

4. Memorandum of Association: Revised MOA adopted with new objects related to technology-driven healthcare solutions, AI systems, digital health platforms, and healthcare services.

Dividend

No dividend declared during FY 2025-26.

Transfer to Investor Education and Protection Fund (IEPF)

  • Transferred ₹74,117.40 pertaining to 1st Interim Dividend for FY 2018-19
  • ₹94,106.70 (2nd Interim Dividend FY 2018-19) due for transfer on March 19, 2026
  • ₹2,54,817.20 (Final Dividend FY 2018-19) due for transfer on September 14, 2026

Corporate Governance

  • Board met 15 times during FY25-26
  • Separate meeting of Independent Directors held on February 14, 2026
  • All applicable committees constituted (Audit, Nomination & Remuneration, Stakeholders Relationship, Risk Management)
  • Whistle Blower Policy implemented
  • No complaints of sexual harassment during the year

Regulatory Non-Compliances Reported

1. Delay in filling casual vacancy of Whole-time Director, resulting in non-compliance in Board composition

2. Resignation of statutory auditors without giving audit report for quarter/year ended March 31, 2026

3. Delay in appointment of Chief Financial Officer within three months from vacancy date

4. Delay in disclosure of director resignation

5. Delay in appointment of Company Secretary and Compliance Officer

6. Non-filing of e-form MGT-14 for appointment of Company Secretary

Key Ratios

Standalone (FY26)

  • Current Ratio: 13.47 times
  • Return on Equity: 9.54%
  • Trade Payables Turnover Ratio: 6.80 times
  • Return on Capital Employed: 11.11%

Consolidated (FY26)

  • Current Ratio: 4.54 times
  • Return on Equity: 35.00%
  • Trade Receivables Turnover Ratio: 248.41 times
  • Trade Payables Turnover Ratio: 43.14 times
  • Net Profit Ratio: 20.02%
  • Return on Capital Employed: 15.37%

Important Dates

  • AGM Date: September 29, 2026
  • E-voting Period: September 26-28, 2026
  • Record Date: September 22, 2026
  • Financial Results Publication:
  • Q1 FY27: on or before August 14, 2026
  • Q2 FY27: on or before November 14, 2026
  • Q3 FY27: on or before February 14, 2027
  • Q4 FY27: on or before May 30, 2027

Registrar and Transfer Agent

M/s. MUFG Intime India Private Limited

C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai-400 083

Contact: +91-8108116767